| Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use FH Ebetino, S Sun, P Cherian, S Roshandel, JD Neighbors, E Hu, ... Bone 156, 116289, 2022 | 45 | 2022 |
| Targeting anti-cancer agents to bone using bisphosphonates L Xing, FH Ebetino, RK Boeckman Jr, V Srinivasan, J Tao, TK Sawyer, J Li, ... Bone 138, 115492, 2020 | 34 | 2020 |
| Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice H Wang, L Xiao, J Tao, V Srinivasan, BF Brendan, OOB Ebetino H. Frank, ... Pharmaceutics 10 (3), 154, 2018 | 32 | 2018 |
| Bisphosphonates for delivering drugs to bone S Sun, J Tao, PP Sedghizadeh, P Cherian, AF Junka, E Sodagar, L Xing, ... British journal of pharmacology 178 (9), 2008-2025, 2021 | 27 | 2021 |
| Targeting bortezomib to bone increases its bone anabolic activity and reduces systemic adverse effects in mice H Wang, H Zhang, V Srinivasan, J Tao, W Sun, X Lin, T Wu, BF Boyce, ... Journal of Bone and Mineral Research 35 (2), 343-356, 2020 | 21 | 2020 |
| Targeting notch inhibitors to the myeloma bone marrow niche decreases tumor growth and bone destruction without gut toxicity HM Sabol, AJ Ferrari, M Adhikari, T Amorim, K McAndrews, J Anderson, ... Cancer research 81 (19), 5102-5114, 2021 | 15 | 2021 |
| Discovery libraries targeting the major enzyme classes: The serinehydrolases K Otrubova, V Srinivasan, BL Dale Bioorganic & Medicinal Chemistry Letters 24 (16), 3807-3813, 2014 | 13 | 2014 |
| The Notch pathway regulates the bone gain induced by PTH anabolic signaling TB Jesus Delgado-Calle, Kevin McAndrews, Gerald Wu, Ashley L. Orr, Adam ... The Journal of the Federation of American Societies for Experimental Biology …, 2022 | 7* | 2022 |
| Bone‐Targeted Bortezomib Inhibits Bortezomib‐Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone J Tao, V Srinivasan, X Yi, Y Zhao, H Zhang, X Lin, X Zhou, BF Boyce, ... Journal of Bone and Mineral Research 37 (4), 629-642, 2020 | 5 | 2020 |
| Bone-targeted pharmacological inhibition of Notch signaling potentiates PTH-induced bone gain J Delgado-Calle, G Wu, ME Olson, K Mcandrews, JH Nelson, AL Daniel, ... JOURNAL OF BONE AND MINERAL RESEARCH 33, 80-80, 2018 | 3 | 2018 |
| Low doses of the bone-targeted Notch inhibitor BT-GSI exhibit higher anti-myeloma activity and preserve bone compared to unconjugated GSI or zolendronic acid DCJ Amorim T, Ferrari A, Sabol H, Anderson J, Cregor M, Sweet M, Srinivasan ... Journal of Bone and Mineral Research 35 (S1), 101, 2020 | 1 | 2020 |
| Bone-targeting Bortezomib significantly increases its efficacy in the treatment of human multiple myeloma in vitro and in vivo in mice V Tao, J., Srinivasan, X Zhou, FH Ebetino, RK Boeckman Jr, B Boyce, ... J Bone Miner Res 33 (S1), 45, 2018 | 1 | 2018 |
| Bimodal Bone-Targeted Therapy Repairs Damage Bone and Overcomes Drug Resistance in Multiple Myeloma DCJ Sabol H, Adhikari M, Ashby C, Anloague A, Kaur J, Khan S, Palmieri M ... Journal of Bone and Mineral Research 38 (S2), 1, 2023 | | 2023 |
| Bone-Targeted Bortezomib Increases Bone Formation within Calvarial Trans-sutural Distraction Osteogenesis HW Hongyu Chen, Guanhui Cai, Venkatesan Srinivasan, Xiaorui Ruan, Yahui Lu ... Bone 169, 116677, 2023 | | 2023 |
| Dual anti-resoptive and anabolic effect of bone target hydroxychloroquine for the prevention and treatment of Osteoporosis BB Yao Z, Ayoub A, Hou X, Duan R, Srinivasan V, Xing L, Ebetino F H ... Journal of Bone and Mineral Research 37 (S1), 338, 2022 | | 2022 |
| Bone-targeted inhibition of notch signaling blocks tumor growth and prevents bone loss without inducing gut toxicity in immunodeficient and immunocompetent murine models of … F A., MA K., N J., B J., R D., B T., J Delgado-Calle, S V., FH Ebetino, ... J Bone Miner Res 34 (S1), 32, 2019 | | 2019 |
